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Abstract: Cutaneous squamous cell carcinomas (cSCCs) account for about 20% of keratinocyte
carcinomas, the most common cancer in the UK. Therapeutic options for cSCC patients who develop
metastasis are limited and a better understanding of the biochemical pathways involved in cSCC
development/progression is crucial to identify novel therapeutic targets. Evidence indicates that
the phosphoinositide 3-kinases (PI3Ks)/Akt pathway plays an important role, in particular in
advanced cSCC. Questions remain of whether all four PI3K isoforms able to activate Akt are involved
and whether selective inhibition of specific isoform(s) might represent a more targeted strategy.
Here we determined the sensitivity of four patient-derived cSCC cell lines to isoform-specific PI3K
inhibitors to start investigating their potential therapeutic value in cSCC. Parallel experiments were
performed in immortalized keratinocyte cell lines. We observed that pan PI3Ks inhibition reduced the
growth/viability of all tested cell lines, confirming the crucial role of this pathway. Selective inhibition
of the PI3K isoform p110α reduced growth/viability of keratinocytes and of two cSCC cell lines while
affecting the other two only slightly. Importantly, p110α inhibition reduced Akt phosphorylation
in all cSCC cell lines. These data indicate that growth and viability of the investigated cSCC cells
display differential sensitivity to isoform-specific PI3K inhibitors.
Keywords: cutaneous squamous cell carcinoma; phosphoinositide 3-kinases; mTOR; isoform-specific
PI3K inhibitors; BYL719
1. Introduction
Keratinocyte carcinomas (KCs) are the most common cancers in the UK, with over
210,000 tumors reported in 2015 [1]. KCs derive from epidermal keratinocytes, specialized
cells that proliferate in the basal layer of the epidermis and differentiate as they migrate
towards the surface of the skin where they form a tough keratinized layer known as the
stratum corneum [2]. KCs are divided into basal cell carcinomas and cutaneous squamous
cell carcinomas (cSCCs), with cSCC accounting for about 20% of KCs diagnoses [3]. Mor-
tality rate of cSCC patients who develop metastasis is very high [4] because of the limited
therapeutic options for this subset of patients, mainly due to a limited knowledge of the
genetic drivers of metastasis [5]. Cemiplimab, a programmed death-1 receptor blocking
antibody, belonging to the group of immune checkpoint inhibitors (ICI), was approved
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by the Food and Drug Administration in 2018 for patients with metastatic cSCC or locally
advanced cSCC who are not candidates for curative surgery or curative radiation [6].
It remains the only approved systemic therapy, having been confirmed recently as the
recommended first line treatment for these patients [6,7]. The use of ICI in organ trans-
plant recipients and other patients on immunosuppressive medication, however, is still
limited [6,8]. Furthermore, results from a phase I/II clinical trial of cemiplimab showed
that the best overall response rate was 50% in the phase I and 48% in the phase II cohort [9].
A better understanding of the biochemical pathways involved in cSCC development and
progression is crucial to identify novel potential therapeutic targets.
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that catalyze the phos-
phorylation of the 3′ position within the inositol ring of distinct phosphoinositides [10,11].
Eight mammalian PI3Ks exist, grouped into three classes [12], and they regulate activation
of several proteins through synthesis of specific lipid products, ultimately controlling many
cellular functions, including proliferation, survival, migration and metabolism [13,14]. The
isoforms belonging to the class I subgroup, are solely responsible for the synthesis of phos-
phatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P3] in vivo and are dimers of a regulatory
and one of four catalytic subunits, namely p110α, p110β, p110δ and p110γ [12]. The best
characterized amongst all proteins activated by class I PI3Ks is the Serine/Threonine kinase
Akt [15], whose mechanism of activation involves its translocation to the plasma membrane,
induced by binding of its pleckstrin homology domain to PtdIns(3,4,5)P3, and subsequent
phosphorylation at its residues Thr308 and Ser473. Once activated, Akt regulates a plethora
of proteins, including mechanistic (or mammalian) target of rapamycin (mTOR), a master
kinase that controls several cellular functions, such as protein synthesis, ribosome biogene-
sis, cell growth and autophagy [16,17]. The pathway is negatively regulated by the tumor
suppressor Phosphatase and tensin homolog (PTEN) that dephosphorylates PtdIns(3,4,5)P3
thus preventing Akt activation [18].
The PI3K/Akt/mTOR signaling pathway is important for epidermal homeosta-
sis [19–21], as strongly indicated by a number of severe disorders known as PTEN hamar-
toma tumor syndromes which are caused by germline mutations of PTEN and are char-
acterized by hyperplastic changes in the skin [22]. Additional lines of evidence include
data from animal models, such as mice bearing a keratinocyte-specific PTEN null mutation
which are characterized by epidermal hyperplasia and hyperkeratosis [23], mice with
ablation of two of the three Akt isoforms, Akt1 and Akt2, which lack the stratum corneum
and die neonatally, possibly because of defects in the skin barrier [24] and mice carrying an
epidermis-specific deletion of mTOR which die shortly after birth due to impaired early
epidermal differentiation and lack of a protective barrier development [25].
Consistent with its role in epidermal homeostasis, evidence also suggests that the
PI3K/Akt/mTOR pathway is important during cSCC development and progression [26].
Activation of a number of key proteins involved in this pathway was detected in human
cSCC by reverse phase protein microarray analysis [27]. Phosphorylation of Akt, mTOR
and downstream effectors was also observed more frequently in malignant compared to
benign epidermal tumors or normal skin [28]. In addition, a study showed upregulation of
Akt2, with parallel downregulation of Akt1, in cSCC, with high Akt2 expression and high
levels of phosphorylated Akt observed in all examined poorly differentiated cSCC [29].
The importance of this pathways in skin tumorigenesis is further supported by results
from in vivo studies. Specifically, it was reported that mice bearing a keratinocyte-specific
PTEN null mutation developed tumors more rapidly upon chemical treatment as well
as spontaneous tumors, mostly squamous papillomas, many of which progressed into
invasive cSCC [23]. Additional studies demonstrated that Akt activity was increased
in the two-stage model of mouse skin carcinogenesis [30], and that the enzyme had a
key role in promoting insulin like growth factor-1-mediated mouse skin cancer [31,32].
Consistent with this, transgenic mice expressing increased levels of Akt or constitutively
active Akt in the basal layer were more sensitive to two-stage skin carcinogenesis and to
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the tumor promoter 12-O-tetradecanoylphorbol-13-acetate [33] and overexpression of Akt
in keratinocytes accelerated tumorigenesis in vivo [31].
While the importance of the PI3K/Akt/mTOR pathway is supported by several data,
much less is known about the specific contribution of each distinct class I PI3K isoform to
cSCC. Moreover, whether the use of available isoform-specific inhibitors might represent
a potential therapeutic strategy in cSCC remains to be clarified. Recently, an extensive
characterization of a panel of patient-derived cSCC cell lines has been reported, validating
their use for preclinical testing [34]. Here, we investigated the sensitivity of some of
these cells to selective class I PI3Ks inhibitors to identify the main isoform(s) involved in
regulation of their growth, viability and Akt activation, and to start evaluating the potential
therapeutic value of these inhibitors in cSCC.
2. Results
2.1. Expression of Class I PI3K Isoforms in Keratinocytes and cSCC Cell Lines
Several lines of evidence indicate that the PI3K/Akt/mTOR pathway is critical for
keratinocytes [19–21] and cSCC [26–33]. In order to assess the potential therapeutic value
of targeted inhibition of this pathway, we first determined the expression profile of class I
PI3Ks in a panel of recently characterized cSCC cell lines [34,35] compared to immortalized
keratinocyte cell lines. Lysates were analyzed by Western blotting and signals were visualized
by using either a film processor (Figure 1a,c; Supplementary Figure S1a–c) or an imaging
system (Figure 1b,d; Supplementary Figure S1d), as specified in the Methods. Attention was
focused on class I isoforms as these enzymes are mainly responsible for Akt/mTOR activation
in vivo. Data confirmed endogenous expression of the class I isoforms p110α and p110β
in the immortalized keratinocytes HaCaT (Figure 1a,c), N-TERT (Figure 1; Supplementary
Figure S1a,b,d) and Neb1 (Figure 1b,d; Supplementary Figure S1d), consistent with previous
data reporting expression of these enzymes in keratinocytes [20]. Expression of p110α was
also detected in a panel of cSCC cell lines, namely IC1 (Figure 1a; Supplementary Figure S1a),
IC8 (Figure 1a,b; Supplementary Figure S1a), Met1 (Figure 1b; Supplementary Figure S1a), T11
(Figure 1b) and T1 (Supplementary Figure S1a). Moreover, densitometry analysis indicated
that expression levels of p110α were similar in all tested cell lines, although possibly slightly
reduced in T11 cells compared to N-TERT (Figure 1b). In contrast to p110α, expression of
p110β varied between the cSCC cells, with IC8 (Figure 1c,d; Supplementary Figure S1b,d),
T11 (Figure 1d; Supplementary Figure S1d) and T1 (Supplementary Figure S1b) displaying
much lower levels of the enzyme compared to the other cSCC cells and to the immortalized
keratinocytes. No major differences in the levels of either Tubulin or Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was observed between the cell lines (Supplementary
Figure S1c) and similar results were obtained when levels of p110β were normalized to either
Tubulin (Figure 1d) or GAPDH (Supplementary Figure S1d), validating their use as loading
control in these experiments.
Expression of p110γ and p110δ was also observed (Supplementary Figure S2). These
data confirmed that class I PI3K isoforms are detectable in keratinocytes and cSCC cells. Based
on these results, we focused our investigation on the cSCC cell lines Met1 and IC1, which
express similar levels of p110α and p110β compared to the immortalized keratinocytes, and
on IC8 and T11 cells which express comparable (IC8) or slightly lower (T11) levels of p110α
and very reduced levels of p110β compared to the immortalized keratinocytes.
2.2. Effect of PI3K/Akt/mTOR Pathway Inhibition on Keratinocytes and cSCC Cell Lines
Having confirmed expression of class I PI3K isoforms, we next determined whether
these enzymes were involved in regulation of growth and viability of the selected cell
lines. First, we observed that treatment with the pan PI3K inhibitor LY294002 reduced the
number of N-TERT and Neb1 cells (Figure 2a) as well as their viability assessed by MTT
assays (Figure 2b). Treatment with the mTOR inhibitor rapamycin also reduced numbers
(Figure 2c) and viability (Figure 2d) of N-TERT cells, consistent with data in the literature
indicating the crucial role of the PI3K/Akt/mTOR pathway in keratinocytes [19–21].
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Figure 1. Keratinocyte and cutaneous squamous cell carcinoma (cSCC) cell lines express class I phosphoinositide 3-kinase 
(PI3K) isoforms p110α and p110β. Immortalized keratinocytes (HaCaT, N-TERT and Neb1, labelled in blue) and cSCC 
cells (IC1, IC8, Met1 and T11) were lysed with 2% SDS and expression of the indicated class I PI3K isoforms was analyzed 
by Western blotting. Tubulin was used as loading control. Signals were visualized using X -ray films and a film processor 
(a,c) or using Chemidoc™ MP Imaging System (b,d). Representative blots are shown. Graphs indicate data from densi-
tometry analysis for each enzyme, normalized to Tubulin and expressed as fold change of results from N-TERT cells. Data 
are means ± SEM from the following numbers of lysates, prepared independently from different batches of cells: n = 6 ((a), 
apart from IC1, n = 5), n = 3 (b), n = 6 (c) and n = 3 ((d), apart from T11, n = 1). Note that p110β was barely detectable and 
not quantifiable in IC8 cells using Chemidoc™ MP Imaging System (d) therefore densitometry analysis could not be per-
formed for these cells in these experiments. Similarly, the band was detectable and quantifiable in only one of the T11 
lysates in these conditions therefore only this set (labelled in red) was used for analysis in (d). See also Supplementary 
Figure S1d. ** p < 0.01 vs. N-TERT, # p < 0.05 vs. HaCaT. 
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data confirmed that class I PI3K isoforms are detectable in keratinocytes and cSCC cells. 
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Figure 1. Keratin cyte nd cutaneous squamous cell ca cinoma (cSCC) cell lines express class I
phosphoinositide 3-kinase (PI3K) isoforms p110α and p110β. Immortalized keratinocytes (HaCaT,
N-TERT and Neb1, labelled in blue) and cSCC cells (IC1, IC8, Met1 and T11) were lysed with 2% SDS
and xpression of the indicated class I PI3K isoforms was analyzed by Western blotting. Tubulin
was used as loading control. Signals were visualized using X-ray films and a film processor (a,c) or
using Chemidoc™ MP Imaging System (b,d). Representative blots are shown. Gr phs indicate data
from densitometry analysis for each enzyme, normalized to Tubulin and expressed as fold change of
results from N-TERT cells. Data are means ± SEM from the following numbers of lysates, prepared
independently from different batches of cells: n = 6 ((a), apart from IC1, n = 5), n = 3 (b), n = 6 (c)
and n = 3 ((d), apart from T11, n = 1). Note that p110β was barely detectable and not quantifiable in
IC8 cells using Chemidoc™ MP Imaging System (d) therefore densitometry analysis could not be
performed for these cells in these experim nts. Similarly, the band was detectable and quantifiable in
only one of the T11 lysates in these conditions therefore only this set (labelled in red) was used for
analysis in (d). See also Supplementary Figure S1d. ** p < 0.01 vs. N-TERT, # p < 0.05 vs. HaCaT.
Next, we tested the effect of these inhibitors on the selected cSCC cell lines. Data
showed that treatment with LY294002 (10 µM) reduced number (Figure 3a) and viability
(Figure 3b) of all selected cSCC cells. Inhibition of growth (Supplementary Figure S3a) and
viability (Supplementary Figure S3b) was also detected upon treatment of IC8 and Met1
cells with lower concentrations of LY294002. Similarly, treatment with 10 nM rapamycin
reduced the number of all selected cSCC cell lines (Figure 3c) as well as viability of IC8,
Met1 and T11 cells (Figure 3d). More specifically, rapamycin reduced numbers of IC8 and
Met1 cells in a dose dependent manner (Supplementary Figure S3c). Finally, treatment with
50 nM rapamycin reduced viability of IC1 as well as IC8 and Met1 cells (Supplementary
Figure S3d). Treatment with vehicle alone did not affect numbers and viability of N-TERT
(Supplementary Figure S4a,b), Neb1 (Supplementary Figure S4a,b) and IC8 (Supplementary
Figure S4c,d) cells or viability of Met1 and IC1 cells (Supplementary Figure S4d).
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vestigation of the effect of these inhibitors on immortalized keratinocytes revealed that 
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Figure 3. The PI3K/Akt/mTOR path ay regulates growth and viability of cSCC cell lines. The
indicated cSCC cell lines were treated with 10 µM LY294002 (a,b) or 10 nM rapamycin (c,d) in
complete medium supplemented with 10% FBS. Control cells were treated with vehicle alone (DMSO).
After 72 h, number of cells was assessed by cell counting (a,c) and cell viability was assessed by MTT
assays (b,d). Data are expressed as percentage of results from control cells and are means ± SEM
from n = 4 ((a), IC1, IC8, Met1), n = 7 ((a), IC1); n = 5 ((b), IC8), n = 7 ((b), Met1), n = 4 ((b), T11),
n = 10 ((b), IC1); n = 3 ((c), IC1,T11), n = 6 (( ), Met1), n = 9 ((c), IC8); n = 2 ((d), IC8, Met1) and
n = 3 ((d), T11) independent experiments performed in duplicate (a,c) or triplicate (b,d). * p < 0.05,
** p < 0.01, *** p < 0.001 vs. DMSO.
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Taken together, these data confirmed that the PI3K/Akt/mTOR pathway plays a key
role in keratinocytes and in cSCC cell growth and viability.
2.3. Effect of Isoform-Specific PI3K Inhibitors on Keratinocytes Growth and Viability
To identify the main class I PI3K isoform(s) involved in regulation of keratinocytes and
cSCC growth and viability, cells were treated with isoform-specific PI3K inhibitors, namely
BYL719 (targeting p110α primarily), GSK2636771 (targeting p110β primarily), AS252424
(targeting p110γ primarily) and CAL101 (targeting p110δ primarily). First, investigation of
the effect of these inhibitors on immortalized keratinocytes revealed that BYL719 reduced
both cell numbers (Figure 4a,c) and viability (Figure 4b,d) of N-TERT and Neb1 cells. At
the tested concentration, none of the other inhibitors had an effect, apart from GSK2636771
and CAL101 reducing N-TERT cell numbers significantly but slightly (Figure 4a).
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are expressed as percentage of results from cells treated with DMSO and are means ± SEM from n = 
3 (a), n = 3 (b), n = 3 (c) and n = 4 (d) independent experiments performed in duplicate (a,c) or 
triplicate (b,d). * p < 0.05, ** p < 0.01 vs. DMSO. 
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inhibitor GSK2636771 in N-TERT cells (Figure 4a), we next compared the effects of p110α 
and p110β inhibition by performing a dose response analysis of the effect of BYL719 and 
GSK2636771. Data confirmed that BYL719 had the strongest inhibitory effect on N-TERT 
cell numbers (Supplementary Figure S5a) and viability (Supplementary Figure S5b) at the 
tested concentrations. Similar results were obtained by assessing the effect of the inhibi-
tors on HaCaT cell numbers (Supplementary Figure S5c). As observed for the other cell 
lines used in this study, no effect on cell numbers was detected in untreated HaCaT com-
pared to cells treated with vehicle alone (Supplementary Figure S5d). 
Treatment with BYL719 appeared to reduce cell numbers and viability less than pan 
PI3K inhibition (Figure 2a,b); therefore, we next investigated whether p110β could have 
any compensatory role upon p110α inhibition, as observed in some cancer settings [36,37]. 
To this end, N-TERT cells were treated with BYL719 and GSK2636771 alone or in combi-
nation. Combination of the two compounds did not increase the inhibitory effect of 
BYL719 on N-TERT cell numbers (Figure 5a) and viability (Figure 5b) significantly, com-
pared to treatment with BYL719 alone. 
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of keratinocytes. N-TERT (a,b) and e (c,d) cells were treated with 1 µM of the indicated inhibitors
or vehicle (DMSO) in complete medium supplemented with 10% FBS. After 72 h, number of cells
was assessed by cell counting (a,c) and cell viability was assessed by MTT assays (b,d). Data are
expressed as percentage of results from cells tr ated with DMSO and are me ns± SEM from n = 3 (a),
n = 3 (b), n = 3 (c) and n = 4 (d) independent experiments performed in duplicate (a,c) or triplicate
(b,d). * p < 0.05, ** p < 0.01 vs. DMSO.
As a slight reduction in cell numbers was observed upon treatment with the p110β
inhibitor GSK2636771 in N-TERT cells (Figure 4a), we next compared the effects of p110α
and p110β inhibitio by performing a dose response analysis of the effect of BYL719 and
GSK2636771. Data confi med that BYL719 had th strong st inhibitory effect on N-TERT
cell umbers (Supplementary Figure S5a) and viability (Supplementary Figure S5b) at the
tested concentrations. Similar results were obtained by assessing the effect of the inhibitors
on HaCaT cell numbers (Supplementary Figure S5c). As observed for the other cell lines
used in this study, no effect on cell numbers was detected in untreated HaCaT compared to
cells treated with vehicle alone (Supplementary Figure S5d).
Treatment with BYL719 ppeared to reduce cell numbers and viability less than pan
PI3K inhibition (Figure 2a,b); therefore, we next investigated whether p110β could have any
compensatory role upon p110α inhibition, as observed in some cancer settings [36,37]. To
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this end, N-TERT cells were treated with BYL719 and GSK2636771 alone or in combination.
Combination of the two compounds did not increase the inhibitory effect of BYL719 on N-
TERT cell numbers (Figure 5a) and viability (Figure 5b) significantly, compared to treatment
with BYL719 alone.




Figure 5. p110β does not play a major role in N-TERT growth and viability upon p110α inhibition. N-TERT cells were 
treated with 1 µM of the indicated inhibitors alone or in combination in complete medium supplemented with 10% FBS. 
Control cells were treated with DMSO. After 72 h, number of cells was assessed by cell counting (a) and cell viability was 
assessed by MTT assays (b). Data are expressed as percentage of results from control cells and are means ± SEM from n = 
3 (a) and n = 4 (b) independent experiments performed in duplicate (a) or triplicate (b). * p < 0.05, ** p < 0.01 vs. DMSO. 
Taken together, these data demonstrated that BYL719 inhibits growth and viability 
of keratinocytes more potently than the other inhibitors tested, suggesting that p110α is 
the main PI3K isoform regulating such cellular functions in these cells. 
2.4. Effect of Isoform-Specific PI3K Inhibitors on cSCC Cells Growth and Viability 
Next, we assessed the effect of the inhibitors on the selected cSCC cell lines. We ob-
served that the p110α inhibitor BYL719 clearly reduced the number (Figure 6a,c) and via-
bility (Figure 6b,d) of IC8 and Met1 cells. Treatment of IC8 cells with AS252424 or CAL101 
had a significant effect in the MTT assays (Figure 6b) although AS252424 did not seem to 
reduce numbers of these cells (Figure 6a). A slight reduction in the number of Met1 cells 
was also detected upon treatment with GSK2636771 (Figure 6c). Dose response analysis, 
however, confirmed a stronger inhibitory effect of BYL719 compared to GSK2636771 on 
both IC8 (Supplementary Figure S6a) and Met1 (Supplementary Figure S6c) cell numbers 
as well as IC8 viability (Supplementary Figure S6b). No effect on cell counting or MTT 
assays was observed in Met1 treated with AS252424 or CAL101 at the tested concentration 
(Figure 6c,d). 
Figure 5. p110β does not play a major role in N-TERT growth and viability upon p110α inhibition.
N-TERT c lls wer treated with 1 µM of the indicated inhibitors alone or in combina ion in complete
medium supplemented with 10% FBS. Control cells were treated with DMSO. After 72 h, number
of cells was assessed by cell counting (a) and cell viability was assessed by MTT assays (b). Data
are expressed as percentage of results from control cells and are means ± SEM from n = 3 (a) and
n = 4 (b) independent experim nts performed in duplicate ( ) or triplicate (b). * p < 0.05, ** p < 0.01
vs. DMSO.
Taken together, these data demonstrated that BYL719 inhibits growth and viability of
keratinocytes more potently than the other inhibitors tested, suggesting that p110α is the
main PI3K isoform regulating such cellular functions in these cells.
2.4. Effect of Isoform-Specific PI3K Inhibitors on cSCC Cells Growth and Viability
Next, we assessed the effect of the inhibitor on the selected cSCC cell lines. We
observed that the p110α inhibitor BYL719 clearly reduced the number (Figure 6a,c) nd vi-
ability (Figure 6b,d) of IC8 and Met1 cells. Treatment of IC8 cells with AS252424 or CAL101
had a significant effect in the MTT assays (Figure 6b) although AS252424 did not seem to
reduce numbers of these cells (Figure 6a). A slight reduction in the number of Met1 cells
was also detected upon treatment with GSK2636771 (Figure 6c). Dose response analysis,
however, confirmed a stronger inhibitory effect of BYL719 compared to GSK2636771 on
both IC8 (Supplementary Figure S6a) and Met1 (Supplementary Figure S6c) cell numbers
as well as IC8 viability (Supplementary Figure S6b). No effect on cell counting or MTT
assays was observed in Met1 treated with AS252424 or CAL101 at the tested concentration
(Figure 6c,d).
In addition, combination of BYL719 and GSK2636771 did not result in any significant
increase in the effect of the p110α inhibitor on IC8 and Met1 cell numbers (Figure 7a,c) or
viability (Figure 7b,d) compared to treatment with BYL719 alone.
Taken together these data indicate that IC8 and Met1 cells retain the same sensitivity to
PI3K inhibition as normal keratinocytes and suggest that p110α is the main PI3K regulating
growth and viability of these cSCC cell lines.
In contrast to IC8 and Met1 cells, BYL719 had only a very small effect on IC1 (Figure 8a)
and T11 (Figure 8c) cell numbers with reduction not reaching statistical significance in MTT
assays (Figure 8b,d). No effect was detected in MTT assays upon treatment of IC1 cells
with lower concentrations of either BYL719 or GSK2636771 (Supplementary Figure S6d).
None of the other inhibitors affected IC1 or T11 cells at the concentration tested, apart from
CAL101 reducing T11 cell numbers significantly (Figure 8c).
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cell counting (a,c) and cell viability was assessed by MTT assays (b,d). Data are expressed as percentage
of results from cells treated with DMSO and are means ± SEM from n = 3 ((a), apart from AS252424,
n = 6), n = 3 (b), n = 5 ((c), apart from GSK2636771, n = 4) and n = 5 (d) independent experiments
performed in duplicate (a,c) or triplicate (b,d). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. DMSO.
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p < 0.01, *** p < 0.001 vs. DMSO. 
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Figure 7. p110β does not contribute to IC8 and Met1 cell growth and viability upon p110α inhibition.
IC8 (a,b) and Met1 (c,d) cells were treated with 1 µM of the indicated inhibitors alone or in combi-
nation in complete medium supplemented with 10% FBS. Control cells were treated with DMSO.
After 72 h, number of cells was assessed by cell counting (a,c) and cell viability was assessed by MTT
assays (b,d). Data are expressed as percentage of results from control cells and are means ± SEM
(apart from (c), means ± SD) from n = 3 (a), n = 4 (b), n = 3 ((c), apart from GSK2636771, n = 2)
and n = 6 (d) independent experiments performed in duplicate (a,d) or triplicate (b,d). * p < 0.05,
** p < 0.01, *** p < 0.001 vs. DMSO.




Figure 8. IC1 and T11 cells are more resistant to treatment with isoform-specific PI3K inhibitors than 
IC8 and Met1 cells. IC1 (a,b) and T11 (c,d) cells were treated with 1 µM of the indicated inhibitors 
or vehicle (DMSO) in complete medium supplemented with 10% FBS. After 72 h, number of cells 
was assessed by cell counting (a,c) and cell viability was assessed by MTT assays (b,d). Data are 
expressed as percentage of results from cells treated with DMSO and are means ± SEM from n = 3 
((a), apart from AS252424, n = 4), n = 4 ((b), apart from CAL101 n = 3), n = 4 ((c), apart from CAL101 
n = 5) and n = 4 ((d), apart from AS252424 and CAL101 n = 3) independent experiments performed 
in duplicate (a,c) or triplicate (b,d). * p < 0.05, ** p < 0.01 vs. DMSO. 
Combined results from cell counting and MTT assays indicate that IC1 and T11 cells 
are more resistant to PI3K inhibition, in particular to p110α inhibition, compared to IC8 
and Met1 cells. 
To determine whether resistance to p110α inhibition was due to a compensatory role 
of p110β, we next investigated the effect of simultaneous inhibition of p110α and p110β 
on these cells. Consistent with our previous data, treatment with BYL719 alone reduced 
IC1 (Figure 9a) and T11 (Figure 9c) cell numbers only slightly and it did not have a detect-
able significant effect on MTT assays in either cell line (Figure 9b,d). Importantly, no fur-
ther reduction in cell numbers (Figure 9a,c) and no effect on viability (Figure 9b,d) were 
observed when BYL719 was combined with GSK2636771. 
Figure 8. IC1 and T11 c lls are more resist nt to treatment with isoform-spec fic PI3K inhibitors than
IC8 and Met1 cells. IC1 (a,b) and T11 (c,d) cells were treated with 1 µM of the indicated inhibitors
or vehicle (DMSO) in complete medium supplemented with 10% FBS. After 72 h, number of cells
was asse sed by cell counting (a, ) and c ll viability w s assessed by MTT assays (b,d). Data are
expressed as percentage of results from cells treated with DMSO and are eans ± SEM from n = 3
((a), apart from AS252424, n = 4), n = 4 ((b), apart from CAL101 n = 3), n = 4 ((c), apart from CAL101
n = 5) and n = 4 ((d), apart from AS252424 and CAL101 n = 3) independent experiments performed
in duplicate (a,c) or triplicate (b,d). * p < 0.05, ** p < 0.01 vs. DMSO.
Combined results from cell counting and MTT assays indicate that IC1 and T11 cells
are more resistant to PI3K inhibition, in particular to p110α inhibition, compared to IC8
and Met1 cells.
To determine whether resistance to p110α inhibition was due to a compensatory
role of p110β, we next investigated the effect of simultaneous inhibition of p110α and
p110β on these cells. Consistent with our previous data, treatment with BYL719 alone
reduced IC1 (Figure 9 ) and T11 (Figure 9c) cell numbers only slightly and it did not have
a detectable significant effect on MTT assays in either cell line (Figure 9b,d). Importantly,
no further reduction in cell numbers (Figure 9a,c) and no effect on viability (Figure 9b,d)
were observed when BYL719 was combined with GSK2636771.




Figure 9. p110β does not compensate for p110α inhibition in IC1 and T11 cells. IC1 (a,b) and T11 
(c,d) cells were treated with 1 µM of the indicated inhibitors alone or in combination in complete 
medium supplemented with 10% FBS. Control cells were treated with DMSO. After 72 h, number 
of cells was assessed by cell counting (a,c) and cell viability was assessed by MTT assays (b,d). Data 
are expressed as percentage of results from control cells and are means ± SEM from n = 4 (a), n = 7 
(b) and n = 3 (c,d) independent experiments performed in duplicate (a,c) or triplicate (b,d). * p < 0.05, 
** p < 0.01, *** p < 0.001. 
These data indicate that reduced response to p110α inhibition in IC1 and T11 cells is 
not due to a compensatory mechanism dependent on p110β, as detected in some breast 
cancers [36,37]. Taken together, these data reveal a different sensitivity to PI3K inhibitors 
across a panel of cSCC cell lines. 
2.5. Effect of Isoform-Specific PI3K Inhibitors on Akt Activation in cSCC Cells 
In order to determine whether the limited response to isoform-specific inhibitors ob-
served in IC1 and T11 cells was due to an intrinsic resistance to PI3K inhibition, we next 
assessed the effect of these compounds on Akt activation in the selected cSCC cell lines. 
Treatment with BYL719 for 1 h strongly inhibited Akt phosphorylation at both Ser473 and 
Thr308 residues in Met1 cells without affecting the levels of total Akt, as determined by 
Western blotting followed by visualization using either Chemidoc™ MP Imaging system 
(Figure 10) or a film processor (Supplementary Figure S7). Similar results were obtained 
in IC8 cells (Supplementary Figure S8). No inhibition of Akt phosphorylation was de-
tected when cells were treated with the other inhibitors at the tested concentration, apart 
from a slight reduction of Thr308 phosphorylation in Met1 cells upon treatment with 
CAL101 (Figure 10, Supplementary Figure S7). 
Figure 9. Cont.
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Figure 9. p110β does not compensate for p110α inhibition in IC1 and T11 cells. IC1 (a,b) and T11
(c,d) cells were treated with 1 µM of the indicated inhibitors alone or in combination in complete
medium su plemented with 10% FBS. Control cells were tr ated with DMSO. After 72 h, number of
cells was as es ed by cell ce l viability was a se sed by M T assays (b,d). Data are
expressed as percentage of results from control cells and are eans SEM from n = 4 (a), n = 7 (b)
and n = 3 (c,d) independent experiments performed in duplicate (a,c) or triplicate (b,d). * p < 0.05,
** p < 0.01, *** p < 0.001.
These data indicate that reduced response to p110α inhibition in IC1 and T11 cells is
not due to a compensatory mechanism dependent on p110β, as detected in some breast
cancers [36,37]. Taken together, these data reveal a different sensitivity to PI3K inhibitors
across a panel of cSCC cell lines.
2.5. Effect of Isoform-Specific PI3K Inhibitors on Akt Activation in cSCC Cells
In order to determine whether the limited response to isoform-specific inhibitors
observed in IC1 and T11 cells was due to an intrinsic resistance to PI3K inhibition, we next
assessed the effect of these compounds on Akt activation in the selected cSCC cell lines.
Treatment with BYL719 for 1 h strongly inhibited Akt phosphorylation at both Ser473 and
Thr308 residues in Met1 cells without affecting the levels of total Akt, as determined by
Western blotting followed by visualization using either Chemidoc™ MP Imaging system
(Figure 10) or a film processor (Supplementary Figure S7). Similar results were obtained in
IC8 cells (Supplementary Figure S8). No inhibition of Akt phosphorylation was detected
when cells were treated with the other inhibitors at the tested concentration, apart from
a slight reduction of Thr308 phosphorylation in Met1 cells upon treatment with CAL101
(Figure 10, Supplementary Figure S7).
Treatment of Met1 (Figure 11) and IC8 (Figure 12) cells with increasing concentrations
of BYL719 and GSK2636771 for 1 h confirmed a dose-dependent reduction of Akt phospho-
rylation upon p110α but not p110β inhibition in these cells. Similar results were obtained
upon incubation with the inhibitors for 24 h (Supplementary Figures S9 and S10), although,
in these conditions, treatment with 1 µM GSK2636771 also appeared to affect pSer473
Akt slightly in Met1 cells (Supplementary Figure S9). Reduced Akt phosphorylation was
also observed upon treatment with another p110α inhibitor, A66, but not with the p110γ
inhibitor AS252424 in IC8 (Supplementary Figure S11a) and Met1 (Supplementary Figure
S11b) cells. Preliminary experiments further suggested that combination of BYL719 and
GSK2636771 did not increase or it only slightly increased the effect of BYL719 in IC8 and
Met1 cells respectively (Supplementary Figure S12).




Figure 10. BYL719 inhibits Akt phosphorylation in Met1 cells. Met1 cells were treated with 1 µM of 
the isoform-specific inhibitors in complete medium supplemented with 10% FBS. Control cells were 
treated with DMSO or left untreated (NT). Cells were lysed after 1 h and Akt phosphorylation at 
residues Ser473 and Thr308 as well as total levels of Akt were determined by Western blotting. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as loading control. Signals were 
visualized using Chemidoc™ MP Imaging System. Graphs indicate results from densitometry anal-
ysis of phosphorylated or total Akt normalized to loading control and expressed as fold change of 
results from DMSO-treated cells. Data are means ± SEM from n = 3 independent experiments (apart 
from NT in pSer437 Akt graph, n = 2). * p < 0.05, ** p < 0.01 vs. DMSO; # p < 0.05 vs. NT. 
Treatment of Met1 (Figure 11) and IC8 (Figure 12) cells with increasing concentra-
tions of BYL719 and GSK2636771 for 1 h confirmed a dose-dependent reduction of Akt 
phosphorylation upon p110α but not p110β inhibition in these cells. Similar results were 
obtained upon incubation with the inhibitors for 24 h (Supplementary Figure S9, Supple-
mentary Figure S10), although, in these conditions, treatment with 1 µM GSK2636771 also 
appeared to affect pSer473 Akt slightly in Met1 cells (Supplementary Figure S9). Reduced 
Akt phosphorylation was also observed upon treatment with another p110α inhibitor, 
A66, but not with the p110γ inhibitor AS252424 in IC8 (Supplementary Figure S11a) and 
Met1 (Supplementary Figure S11b) cells. Preliminary experiments further suggested that 
combination of BYL719 and GSK2636771 did not increase or it only slightly increased the 
effect of BYL719 in IC8 and Met1 cells respectively (Supplementary Figure S12). 
Figure 10. BYL719 inhibits Akt phosphorylation in Met1 cells. Met1 cells were treated with 1 µM of the isoform-specific
inhibitors in complete medium supplemented with 10% FBS. Control cells were treated with DMSO or left untreated
(NT). Cells were lysed after 1 h and Akt phosphorylation at residues Ser473 and Thr308 as well as total levels of Akt were
determined by W tern blotting. Glyceraldehyde 3-phosphate dehydrog nase (GAPDH) was used as loading control.
Signals were visu iz d using Chemidoc™ MP Imaging System. Graphs in icate results from densitometry analysis of
phosphorylated or total Akt nor alized to loading control and expressed as fold change of results from DMSO-treated
cells. Data are means ± SEM from n = 3 independent experiments (apart from NT in pSer437 Akt graph, n = 2). * p < 0.05,
** p < 0.01 vs. DMSO; # p < 0.05 vs. NT.




Figure 11. BYL719 inhibits Akt phosphorylation in Met1 cells in a dose-dependent manner. Met1 
cells were treated with the indicated concentrations of BYL719 and GSK2636771 in complete me-
dium supplemented with 10% FBS. Control cells were treated with DMSO or left untreated (NT). 
Figure 11. Cont.
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Figure 11. BYL719 inhibits Akt phosphorylation in Met1 cells in a dose-dependent manner. Met1 
cells were treated with the indicated concentrations of BYL719 and GSK2636771 in complete me-
dium supplemented with 10% FBS. Control cells were treated with DMSO or left untreated (NT). 
Figure 11. BYL719 inhibits Akt phosphoryla ion in Met1 c lls in a dose-dependent manner. Met1
cells were treated with the indicated concentrations of BYL719 and GSK2636771 in complete medium
supplemented with 10% FBS. Control cells were treated with DMSO or left untreated (NT). After
1 h, cells were Lysed and lysates were analyzed by Western blotting. GAPDH was used as loading
control. Signals were visualized using Chemidoc™ MP Imaging System. Graphs indicate results from
densitometry analysis of phosphorylated or total Akt normalized to loading control and expressed
as fold change of results from DMSO-treated cells. Data are means ± SEM from n = 3 independent
experiments (apart from data from cells treated with BYL719 1 nM, 10 nM and 100 nM, n = 4)
* p < 0.05, ** p < 0.01, *** p < 0.001 vs. DMSO; # p < 0.05, ## p < 0.01 vs. NT.
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were left untreated (NT) or treated for 1 h with increasing concentrations of BYL719 and 
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DMSO. Phosphorylation status and total levels of Akt were analyzed by Western blotting. GAPDH 
was used as loading control. Signals were visualized using Chemidoc™ MP Imaging System. 
Graphs show results from densitometry analysis of phosphorylated or total Akt normalized to load-
ing control and expressed as fold change of results from DMSO-treated cells. Only blots showing 
clearly detectable bands were used for densitometry analysis. Data are means ± SEM from the fol-
lowing numbers of independent experiments: pSer473 Akt, n = 4 (apart from NT in BYL719 graph 
and from BYL719 1 nM, BYL719 10 nM and GSK2636771 100 nM, n = 3); pThr308 Akt, n = 4 (apart 
Figure 12. Cont.
Int. J. Mol. Sci. 2021, 22, 3567 13 of 22
Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 15 of 25 
 
 
After 1 h, cells were Lysed and lysates were analyzed by Western blotting. GAPDH was used as 
loading control. Signals were visualized using Chemidoc™ MP Imaging System. Graphs indicate 
results from densitometry analysis of phosphorylated or total Akt normalized to loading control 
and expressed as fold change of results from DMSO-treated cells. Data are means ± SEM from n = 3 
independent experiments (apart from data from cells treated with BYL719 1 nM, 10 nM and 100 nM, 
n = 4) * p < 0.05, ** p < 0.01, *** p < 0.001 vs. DMSO; # p < 0.05, ## p < 0.01 vs. NT. 
 
Figure 12. BYL719 inhibits Akt phosphorylation in IC8 cells in a dose-dependent manner. IC8 cells 
were left untreated (NT) or treated for 1 h with increasing concentrations of BYL719 and 
GSK2636771 in complete medium supplemented with 10% FBS. Control cells were treated with 
DMSO. Phosphorylation status and total levels of Akt were analyzed by Western blotting. GAPDH 
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Figure 12. BYL719 inhibits Akt phosphorylation in IC8 cells in a dose-dependent mann r. IC8
ce ls were left untreated (NT) or treated for 1 with increasing concentrati ns of BYL719 and
GSK2636771 in complet medium supplemented with 10% FBS. C ntrol cells were treated with
DMSO. Phosphorylation status and total levels of Akt were analyzed by Western blotting. GAPDH
was used as loading control. Signals were visualized using Chemidoc™ MP Imaging System. Graphs
show results from densitometry analysis of phosphorylated or total Akt normalized to loading
control and expressed as fold change of results from DMSO-treated cells. Only blots showing clearly
detectable bands were used for densitometry analysis. Data are means ± SEM from the following
nu bers of independent experiments: pSer473 Akt, n = 4 (apart from NT in BYL719 graph and from
BYL719 1 nM, BYL719 10 nM and GSK2636771 100 nM, n = 3); pThr308 Akt, n = 4 (apart from BYL719
1 nM, 10 nM and 100 nM, n = 3 and BYL719 1 µM, n = 2); Akt, n = 4 (apart from NT, n = 3); ** p < 0.01,
*** p < 0.001 vs. DMSO; # p < 0.05, ## p < 0.01 vs. NT.
Taken together these data demonstrate that p110α is the main isoform regulating Akt
activation in IC8 and Met1 cells, consistent with data on cell growth and viability.
We next investigated the effect of the isoform-specific inhibitors on T11 and IC1 cells.
Data revealed that treatment with BYL719 for 1 h was able to inhibit Akt phosphorylation
in T11 cells without affecting total levels of Akt (Figure 13, Supplementary Figure S13),
similarly to results obtained in Met1 and IC8 cells. None of the other inhibitors affected
Akt phosphorylation at the tested concentration (Figure 13, Supplementary Figure S13).
Dose response analysis confirmed inhibition of Akt phosphorylation in T11 cells
treated with BYL719 but not with GSK2636771 (Figure 14).
Inhibition of Akt phosphorylation was also detected in IC1 cells upon 1 h (Supplementary
Figure S14a) or 24 h (Supplementary Figure S14b) treatment with BYL719.
These data indicate that BYL719 inhibits Akt activation in all cSCC cell lines. Together
with our previous data, these results indicate that the limited effect of BYL719 on IC1
and T11 cell growth and viability is not due to a generic lack of response to the drug in
these cells.
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Figure 14. BYL719 inhibits Akt phosphorylation in T11 cells in a dose-dependent manner. T11
cells were treated for 1 h with increasing concentrations of BYL719 and GSK2636771 in complete
medium supplemented with 10% FBS. Control cells were left untreated (NT) or treated with DMSO.
Phosphorylation and total levels of Akt were analyzed by Western blotting, with GAPDH used as
loading control. Signals were visualized using Chemidoc™ MP Imaging System. Graphs show
results from densitometry analysis of phosphorylated or total Akt normalized to loading control
and expressed as fold change of results from DMSO-treated cells. Data are means ± SEM from the
following numbers of independent experiments: pSer473 Akt, n = 3 (apart from GSK2636771 1 µM,
n = 2); pThr308 Akt, n = 3 (apart from NT i BYL719 graph and GSK2636771 1 µM, n = 2); Akt, n = 3
(apart from NT in BYL719 g aph and GSK2636771 100 nM a 1 µM, n = 2); ** p < 0.01 vs. DMSO;
## p < 0.01 vs. NT.
3. Discussion
Data in the literature indicate that the PI3K/Akt/mTOR pathway could be a valid
target in cSCC [26,38]. The potential beneficial effects of targeting mTOR is supported by
preclinical studies [39–42] as well as evidence from organ transplant recipients [43–47],
who have increased risk of cSCC because of prolonged immunosuppression [8]. Whether
targeting selective PI3K isoforms can also prove beneficial remains to be fully established.
In this study we assessed the sensitivity to pan and isoform-specific PI3K inhibition of
four cell lines, part of a recently described panel of patient-derived cSCC cell lines [34,35].
Importantly, published cSCC cell lines are few and this panel is among the largest [34,35].
The effect of the inhibitors on growth and viability of immortalized keratinocyte cell lines
was also investigated. We show that simultaneous inhibition of all PI3K isoforms or
blockade of mTOR reduced growth and viability of all investigated cell lines. As the tested
cSCC cells derive from either moderately or poorly differentiated primary tumors [34],
these results are consistent with data from our previous mutational pathway analysis
of 40 primary cSCC tumors that identified the PI3K/Akt pathway amongst the KEGG
signaling pathways that were more mutated in the moderately differentiated/poorly
differentiated group [35].
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Using isoform-specific inhibitors we further show that the p110α inhibitor BYL719
inhibited growth and viability of the cSCC cell lines IC8 and Met1 more potently than any
of the other inhibitors. Similar results were obtained in immortalized keratinocyte cell
lines. On the other hand, neither BYL719 nor any of the other selective inhibitors had any
major or consistent effect on both cell counting and MTT assays in the cSCC cell lines IC1
and T11, when used at a concentration of 1 µM. These data indicate that, while growth
and viability of all investigated cSCC cells is reduced by pan PI3Ks or mTOR inhibition,
sensitivity to selective PI3K inhibitors, in particular to BYL719, differs between these cells.
It remains to be established whether these inhibitors might affect growth and viability of
IC1 and T11 cells if used at concentrations higher than 1 µM. In this respect, it must be
noted that treatment with 1 µM of GSK2636771 [48] or AS252424 [49] was able to reduce
the number of prostate cancer PC3 cells [48] and pancreatic cancer HPAF-II and Capan1
cells [49] respectively. Similarly, 1 µM CAL101 induced apoptosis in diffuse large B-cell
lymphoma, follicular lymphoma and B-cell acute lymphoblastic leukemia cell lines [50].
These data suggest that the concentration of the inhibitors used in this study should be
able to inhibit their target PI3K. On the other hand, as the IC50s of these inhibitors towards
their selective targets are in the low nanomolar range and other PI3Ks might be affected
by high concentrations of the compounds [50–53], the possibility still remains that 1 µM
BYL719 might have blocked more than one isoform in these experiments. Although some
results were confirmed by using lower concentrations of this drug, additional studies
are now required to confirm whether the effect of BYL719 on Met1 and IC8 cells is due
to sole inhibition of p110α. It must be noted that, although the majority of our results
were consistent between the two assays, we detected statistically significant effects on cell
counting but not on MTT assays in a few instances. As this occurred mostly when cell
numbers were only slightly reduced, the apparent discrepancy might be due to a lower
sensitivity of MTT assays in these experiments. On the other hand, the reason for observing
different effects of CAL101 on counting and MTT assays in T11 cells (Figure 8c,d) would
require further investigation. In addition, the p110γ inhibitor AS252424 appeared to have
an effect in MTT but not in cell counting assays in IC8 cells (Figure 6a,b) which might be
due to a specific effect of the inhibitor on mitochondrial activity rather than viability of
these cells. The conclusions discussed in this study are based on results that were consistent
between the two assays.
Overall, our data indicate that growth and viability of IC1 and T11 cells are more
resistant to BYL719 treatment compared to IC8 and Met1 cells. The differential sensitivity
to BYL719 was not due to different expression levels of p110α as this was fairly consis-
tent between all cell lines used in this study. Furthermore, data in the literature indicate
that activating mutations of PIK3CA, detected in many cancers [54], do not occur at high
frequency in primary cSCC [55,56]. Interestingly, clinically-relevant genomic alterations
of PIK3CA have been reported in some recurrent, metastatic cSCC [57] and PIK3CA acti-
vating mutations have been detected in some cSCC lymph node metastases [58]. These
observations, together with results from a recent study reporting the inhibitory effect of the
PI3K inhibitor PIK-75 on cell lines derived from cSCC metastases of the head and neck [59],
strongly suggest that sensitivity to BYL719 should be further investigated in a panel of
metastatic cSCC cells.
Resistance to p110α inhibition has been documented [60–62] and compensatory roles
of other PI3Ks, in particular of p110β, have been described [36,37]. Our observation
that sensitivity to BYL719 did not appear to depend on expression levels of p110β and
that simultaneous inhibition of p110α and p110β did not affect numbers or viability of
IC1 and T11 cells, however, rules out a compensatory role of p110β in the tested cSCC
cells, at least in the experimental conditions used in this study. As cell numbers and
viability of IC1 and T11 cells was strongly inhibited by the pan PI3K inhibitor LY294002
further investigation is required to establish whether other PI3Ks, including members
of the class II subfamily, contribute to growth/viability of these cells in normal growing
conditions or upon p110α inhibition. Overexpression of the receptor tyrosine kinase Axl
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has been involved in resistance to BYL719 in head and neck squamous cell carcinoma
(HNSCC) and esophageal squamous cell carcinoma (ESCC) [62]. Interestingly, Axl not
only is expressed in Met1 and IC1 cells [63] but is also upregulated in Met1 cells compared
to their premalignant cells [64] and in cSCC cells compared to primary normal human
keratinocytes [35]. Moreover, depletion of Axl was shown to reduce resistance of cSCC cell
lines to chemotherapy drugs [63]. Although our experiments were performed within a
short time frame, it would be worth investigating whether an upregulation of Axl might
be involved in the reduced response to BYL719 of IC1 and T11 cells. In this respect, it must
be noted that resistance to BYL719 mediated by Axl occurs through an Akt-independent
mTOR activation in HNSCC and ESCC [62]: this would be consistent with our observation
that growth and viability of both IC1 and T11 cells are reduced by mTOR inhibition.
Recently, it has been reported that combination of BYL719 with a c-Jun N-terminal kinase
inhibitor induced Axl downregulation and mTOR inhibition, resulting in a synergistic
anti-proliferative effect in vitro [65]. It would be interesting to determine whether such a
combination might prove effective on IC1 and T11 cells.
While BYL719 did not affect their viability and growth, it was able to inhibit Akt
activation in IC1 and T11 cells in the experimental conditions used in this study. Whether
a rebound Akt activation occurs in these cells upon longer incubation with the inhibitor
remains to be established. Nonetheless, these data support the conclusion that monitoring
Akt phosphorylation might not be directly indicative of the efficacy of the inhibitor on
viability and growth of cSCC cells, as previously observed in breast cancers [36]. It must
also be noted that phosphorylation of Akt in this study was assessed by using antibodies
that do not discriminate between Akt1 and Akt2. As the two isoforms play distinct roles in
epidermis [66] and are known to be regulated differently during cSCC progression [29], it
would be important to monitor the specific effect of BYL719 on each Akt isoform.
Finally, as it was limited to four cSCC cell lines, our study cannot provide a final
answer to the question of whether targeting specific PI3K(s) might represent a therapeutic
strategy in cSCC, especially considering the many cross talks between this pathway and
other signaling cascades. Important information can be obtained from our data nonethe-
less. Our results have revealed a heterogeneous response of cSCC cell lines to selective
PI3K inhibitors (in particular p110α inhibition), possibly suggesting that sensitivity to
these drugs might be patient-specific. The observation that BYL719 affects growth and
viability of two of the investigated cSCC as well as two immortalized keratinocyte cell
lines, however, might already suggest some limitations in the potential use of this inhibitor.
Clearly, more studies are now needed to validate whether selective PI3K inhibitors have a
therapeutic value in cSCC. Some initial data from this study were presented, as a poster,
at the British Society for Investigative Dermatology Annual Meeting Norcroft Conference
Centre, University of Bradford, Bradford, UK, 1–3 April 2019 [67].
4. Materials and Methods
4.1. Cell Culture and Treatment
cSCC cell lines, previously characterized [34,35], and immortalized keratinocytes
N-TERT and Neb1 cells were cultured in Dulbecco’s Modified Eagle Medium/Nutrient
Mixture F-12 (DMEM/F-12 GlutaMAX™ supplement, Gibco™, Thermo Fisher Scientific,
Waltham, MA, USA, cat no: 10565018). Immortalized keratinocytes HaCaT cells were cul-
tured in DMEM (Gibco™, Thermo Fisher Scientific, Waltham, MA, USA, cat no: 12077549).
Media were supplemented with 10% Fetal Bovine Serum (FBS) (Gibco™, Thermo Fisher
Scientific, Waltham, MA, USA, cat no: 11550356) and 1% Penicillin-Streptomycin (Gibco™,
Thermo Fisher Scientific, Waltham, MA, USA, cat no: 11548876). Cells were incubated at
37 ◦C, 5% CO2. The following inhibitors were used in this study: BYL719 (Cambridge
Bioscience, Cambridge, UK, cat no: CAY16986), GSK2636771 (Generon, Slough, UK, cat no:
B2186), AS252424 (Generon, Slough, UK, cat no: SY-AS-252424), CAL101 (Cambridge Bio-
science, Cambridge, UK, cat no: c0044), LY294002 (Cambridge Bioscience, Cambridge, UK,
cat no: CAY70920), rapamycin (Cambridge Bioscience, Cambridge, UK, cat no: CAY13346),
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A66 (Tocris Bioscience, Bristol, UK, cat no: 5595). Cells were incubated with each inhibitor
at a concentration of 1 µM (unless otherwise stated) in complete medium supplemented
with 10% FBS.
4.2. Cell Counting and MTT Assays
Cells were seeded in 12 well plates (cell counting) or 48 wells (MTT assays) and
treated with the indicated inhibitors 24 h after plating. Control cells were treated with
vehicle alone (DMSO). After 72 h, cells were manually counted using a Burker chamber
and a light microscope at 10x magnification. All experiments were performed in duplicate.
Alternatively, cells were incubated with 500 µg/mL Thiazolyl Blue Tetrazolium Bromide
(MTT, Sigma Aldrich, St. Louis, MO, USA, cat no: M2128) during the last 3 h of incubation.
MTT formazan crystals were then dissolved with DMSO and absorbance at 570 and 650 nM
was measured using an absorbance microplate reader.
4.3. Western Blotting Analysis
Cells were seeded in 6 well plates. For analysis of PI3Ks expression levels, cells in
normal growing conditions were used. Alternatively, cells were treated with inhibitors
for 1 h or 24 h before lysis. For experiments presented in Figures 11, 12 and 14, two 6 well
plates were plated in parallel and used for the BYL719 and GSK2636771 dose response
experiments respectively. In each plate, one well was left untreated (NT) and one was
treated with vehicle (DMSO) alone as controls. Cells were lysed using 2% SDS, followed
by sonication. Protein concentration was assessed using Pierce™ BCA Protein Assay Kit
(Thermo Fisher Scientific, Thermo Scientific™, Waltham, MA, USA, cat no: 23227). Samples
were separated by SDS-PAGE and transferred into nitrocellulose membranes. Membranes
were incubated with 5% skimmed milk in Phosphate-buffered saline supplemented with
0.05% (v/v) Tween 20 (PBS-T) for 30 min at room temperature, followed by overnight
incubation with primary antibodies at + 4 ◦C. Primary antibodies (and the corresponding
dilutions, in PBS-T) were as follow: anti p110α (Cell Signaling Technology, Danvers, MA,
USA, cat no: 4249, 1:1000), anti p110β (Cell Signaling Technology, Danvers, MA, USA, cat
no: 3011, 1:1000), anti p110γ (Cell Signaling Technology, Danvers, MA, USA, cat no: 4252,
1:1000), anti p110δ (Santa Cruz Biotechnology, Dallas, TX, USA, cat no: SC-55589, 1:1000),
anti pSer473 Akt (Cell Signaling Technology, Danvers, MA, USA, cat no: 4060, 1:1000), anti
pThr308 Akt (Cell Signaling Technology, Danvers, MA, USA, cat no: 2965, 1:1000), anti
Akt (Cell Signaling Technology, Danvers, MA, USA, cat no: 4691, 1:1000), anti α-Tubulin
(Sigma Aldrich, St. Louis, MO, USA, cat no: T9026, 1:20,000); anti Vinculin (Sigma Aldrich,
St. Louis, MO, USA, cat no: V9131, 1:10,000); anti GAPDH (Cell Signaling Technology,
Danvers, MA, USA, cat no: 5174, 1:5000). After washing with PBS-T, membranes were
incubated with peroxidase conjugated secondary antibodies (anti-rabbit IgG, cat no: A6154,
1:10,000; anti-mouse IgG, cat no: A0168, 1:10,000, both from Sigma Aldrich, St. Louis, MO,
USA) for 1 h at room temperature, washed with PBS-T and exposed to ECL reagent (Sigma
Aldrich, St. Louis, MO, USA, Immobilon™ Western Chemiluminescent HRP Substrate,
cat no: WBKLS0500). Signals were visualized using X-ray Film 18 cm × 24 cm Double
Sided (Scientific Laboratory Supplies, Nottingham, UK cat no: MOL7016) using a film
processor or using Chemidoc™ MP Imaging System (Bio-Rad, Hercules, CA, USA). For
experiments visualized using X-ray films and a film processor, membranes were cut into
strips around the molecular weight of each protein of interest and incubated with the
corresponding primary antibodies. For experiments visualized using Chemidoc™ Imaging
System, the whole membranes were incubated with the specific primary antibody first.
After visualization, membranes were re-incubated with anti GAPDH or anti Tubulin as
loading control.
5. Conclusions
Although limited to four cSCC cell lines, our study has revealed their differential
sensitivity to selective PI3K inhibition, confirming the highly heterogeneous nature of
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cSCC. This highlights the critical need for reliable experimental tools that can allow careful
preclinical studies. In this respect, this study has contributed further to the characterization
of a panel of cSCC cell lines, which will prove very useful in preclinical testing to identify
novel therapeutic strategies.
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